Flag of the European Union EU Clinical Trials Register Help

Clinical trials for lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,346 result(s) found for: lymphoma. Displaying page 41 of 68.
    «« First « Previous 37  38  39  40  41  42  43  44  45  Next» Last»»
    EudraCT Number: 2021-006030-40 Sponsor Protocol Number: Pola_R Start Date*: 2022-05-31
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med I, Onkologie
    Full Title: EFFICACY OF POLATUZUMAB, BENDAMUSTINE AND RITUXIMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MANTLE CELL LYMPHOMA – A SINGLE CENTER PHASE II TRIAL
    Medical condition: MANTLE CELL LYMPHOMA
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000719-17 Sponsor Protocol Number: PIVeR Start Date*: 2018-03-05
    Sponsor Name:LYSARC
    Full Title: A multicentre, phase II, open label, single arm study of pixantrone in patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma treated with rituximab, ifosfamide and etop...
    Medical condition: Patients with CD20-positive relapsed or refractory aggressive non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10029608 Non-Hodgkin's lymphomas unspecified histology aggressive HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003539-22 Sponsor Protocol Number: ZETAL 07 Start Date*: 2007-11-08
    Sponsor Name:GIMURELL
    Full Title: Two repeated doses of Yttrium-90 labeled Ibritumomab-Tiuxetan (Zevalin) as salvage treatment for patients with relapsed or refractory aggressive B-cell lymphoma: a phase II study.
    Medical condition: Patients with B-DLCL relapsed or refractory after first line of therapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012821 Diffuse large B-cell lymphoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004682-11 Sponsor Protocol Number: AUTO3-DB1 Start Date*: 2017-07-19
    Sponsor Name:Autolus Limited
    Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 with Anti PD-1 Antibody in Patients wi...
    Medical condition: Relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL) and large B cell lymphoma subsets
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    20.0 100000004851 10036711 Primary mediastinal large B-cell lymphomas HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036710 Primary mediastinal large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-002521-23 Sponsor Protocol Number: FOLLREC3 Start Date*: 2006-10-13
    Sponsor Name:G.I.S.L. - GRUPPO ITALIANO STUDIO LINFOMI
    Full Title: Phase II study of VELCADE in combination with Rituximab in patients with relapsed or progressed Non Hodgkin's Follicular Lymphoma
    Medical condition: relapsed or progressed Follicular non Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061170 Follicle centre lymphoma, follicular grade I, II, III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007698-22 Sponsor Protocol Number: R2-CHOP Start Date*: 2008-07-10
    Sponsor Name:GELARC
    Full Title: A PHASE IB/II STUDY OF ESCALATING DOSES OF REVLIMID IN ASSOCIATION WITH R-CHOP (R2-CHOP) IN THE TREATMENT OF B-CELL LYMPHOMA
    Medical condition: B cell lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-012337-29 Sponsor Protocol Number: IILFLE09 Start Date*: 2009-07-20
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: Brief induction chemoimmunotherapy with Rituximab + Bendamustine + Mitoxantrone followed by Rituximab in elderly patients with advanced stage previously untreated follicular lymphoma
    Medical condition: Elderly patients with advanced stage previously untreated follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10016903 Follicle centre lymphomas, follicular grade I, II, III HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002544-32 Sponsor Protocol Number: UCL/15/0515 Start Date*: 2018-03-01
    Sponsor Name:University College London
    Full Title: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first ...
    Medical condition: Relapsed/refractory Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004956-60 Sponsor Protocol Number: UCL/08/0121 Start Date*: 2009-08-14
    Sponsor Name:University College London
    Full Title: Phase II Study of Reduced Intensity Allogeneic Transplantation for Refractory Hodgkin Lymphoma
    Medical condition: Refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-000359-13 Sponsor Protocol Number: ML18167 Start Date*: 2005-06-20
    Sponsor Name:Roche (Magyarország) Kft
    Full Title: Hungarian Study of Maintenance after Rituximab Pretreatment. A multicentre, phase III, open-label study evaluating the benefit of a long-term MabThera® (rituximab) maintenance therapy in patients w...
    Medical condition: Patients with advanced follicular lymphoma after induction of response (CR(u) or PR) with a MabThera® (rituximab)-containing first line regimen
    Disease: Version SOC Term Classification Code Term Level
    7.1 10061170 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-000647-12 Sponsor Protocol Number: ML28881 Start Date*: 2013-06-09
    Sponsor Name:ROCHE S.p.A.
    Full Title: A single arm, multicentre, phase IIIb study to evaluate safety, efficacy and pharmacokinetic (PK) of subcutaneous (SC) rituximab administered during induction phase or maintenance in previously u...
    Medical condition: CD20+ diffuse large B-cell lymphoma or CD20+ follicular non-Hodgkin’s lymphoma grade 1, 2 or 3a
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003876-42 Sponsor Protocol Number: SAKK38/19 Start Date*: 2022-04-29
    Sponsor Name:SAKK
    Full Title: Assessing a ctDNA and PET-oriented therapy in patients with DLBCL. A multicenter, open-label, phase II trial
    Medical condition: Disseminated large B cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10060580 Diffuse large cell lymphoma (Adult T-cell lymphoma/leukemia) (Working Formulation) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002630-17 Sponsor Protocol Number: NBK132/2/2021 Start Date*: 2022-02-02
    Sponsor Name:Medical Unicersity of Gdansk
    Full Title: Treatment of nivolumab (N) followed by chemotherapy: bendamustine, gemcitabine and Dexamethasone (BGD) with autologous bone marrow transplantation in lymphoma patients Hodgkin resistant to treatmen...
    Medical condition: Refractory / relapsed Hodgkin's lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-012432-32 Sponsor Protocol Number: IELSG 32 Start Date*: 2010-03-25
    Sponsor Name:IELSG-International Extranodal Lymphoma Study Group
    Full Title: Randomized phase II trial on primary chemotherapy with high-dose methotrexate and high-dose cytarabine with or without thiotepa, and with or without rituximab, followed by brain irradiation vs. h...
    Medical condition: newly diagnosed primary CNS lymphoma in immunocompetent patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036685 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022422-32 Sponsor Protocol Number: RHMCAN0749 Start Date*: 2010-12-20
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib
    Medical condition: Diffuse Large B-cell Lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-004794-16 Sponsor Protocol Number: 1270.11 Start Date*: 2015-10-21
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: An open label multicenter Phase Ib/II trial to determine the dose of BI 836826 in combination with gemcitabine and oxaliplatin (GemOx) and the efficacy of BI 836826 – GemOx versus rituximab ( R ) w...
    Medical condition: Patients with relapsed/refractory diffuse large B-cell lymphoma including transformed follicular lymphoma) who have been previously treated with an anti-CD20 monoclonal antibody (e.g. rituximab) in...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001624-22 Sponsor Protocol Number: INCB50465-203 Start Date*: 2018-04-12
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma
    Medical condition: Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) DK (Completed) SE (Completed) DE (Completed) HU (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005220-26 Sponsor Protocol Number: ACE-LY-308 Start Date*: 2017-05-16
    Sponsor Name:Acerta Pharma BV
    Full Title: A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Un...
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10026798 Mantle cell lymphomas HLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) GR (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002966-29 Sponsor Protocol Number: CCTL019H2301 Start Date*: 2018-11-22
    Sponsor Name:Novartis Pharma AG
    Full Title: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
    Medical condition: adult patients with aggressive B-cell NHL after failure of rituximab and anthracycline containing first line immunochemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) FR (Trial now transitioned) NL (Trial now transitioned) BE (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000999-26 Sponsor Protocol Number: 13-006 Start Date*: 2014-09-20
    Sponsor Name:Jazz Pharmaceuticals, Inc.
    Full Title: An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (asparaginase Erwinia chrysanthemi)/Erwinase® (crisantaspase) Administered Following Hypersensitivity to E. c...
    Medical condition: 1) Acute Lymphoblastic Leukemia 2) Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    17.0 100000004851 10036544 Precursor T-lymphoblastic lymphomas/leukaemias HLT
    17.0 100000004851 10036524 Precursor B-lymphoblastic lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 37  38  39  40  41  42  43  44  45  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 18:44:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA